Upcoming Issue Highlights
Home Subscribe Advertise Sourcebook Free Product Info Home

Lesaffre Completes Full Acquisition of Gnosis


Lesaffre (France) has announced the full acquisition of Gnosis, an Italian biotechnology company specialized in the development, manufacturing and sale of fermentation-derived ingredients and natural finished products for use in the pharmaceutical, nutraceutical, veterinary and cosmetic industries, three years after acquiring a majority shareholding of the company.

Non-GMO Project

Founded in 1989, Gnosis has experienced strong growth since its inception. It now possesses skills and expertise in microbial fermentation and in the recovery and purification of molecules derived from yeasts and bacteria. Gnosis owns two GMP (good manufacturing practice) manufacturing sites (Sant’Antonino in Switzerland and Pisticci in Italy) and two commercial offices (USA and China). The company’s offices and R&D facility are based at Desio, near Milan.

Lesaffrev created the business unit Lesaffre Human Care in 2007. Its mission has been to develop and supply ingredients issued from yeast and bacteria fermentation to the global human care industries. From nutritional and fortified yeasts to yeast fractions, probiotic yeasts and bacteria, or pure molecules, Lesaffre Human Care targets a wide range of applications: digestive health, immunity enhancement, joints and liver health, woman’s health vegetarian support, overall wellbeing and personal care.

By completing the full acquisition of Gnosis, Lesaffre is combining Gnosis and Lesaffre Human Care teams into a single unit to propose a unified range of products and services to its nutritional ingredients and human health customers and partners and to continue its growth in this fast-growing environment.

“For the past three years, we have developed the cooperation between Lesaffre and Gnosis teams to become today a unique provider of products and services that are increasingly innovative and closely address our customer’s needs in the Nutrition and Health sectors,” said Antoine Baule, Lesaffre’s CEO.

“Developing Gnosis has been an exciting challenge. After 25 years, Gnosis has become a reference on the market able to design and manufacture fermentation purified metabolites as Health Care Active Ingredients for the nutraceutical and pharmaceutical markets,” added Renzo Berna, former CEO of Gnosis.“I am convinced that Lesaffre, a family group known and recognized internationally for its professionalism and the quality of its products and services will take this company even further forwards.”

For more information, visit www.lesaffre.com or www.gnosis-bio.com.